Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Case report

A late, solitary brain metastasis of epithelial ovarian carcinoma

Authors: Raffaele Longo, Christian Platini, Nada Eid, Clémence Elias-Matta, Thaar Buda, Denis 'Nguyen, Philippe Quétin

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Brain metastasis from epithelial ovarian cancer (EOC) is very rare with a reported incidence of less than 2%. It is usually associated with a poor prognosis that is related to several factors, the most important including: single vs multiple lesions, performance status, platinum-sensitive disease, tumor grade, extracranial disease, and multimodal approach treatment. At the time of diagnosis, an extracranial disease is found in over half of patients. The most common histology is the serous type. The median time from primary diagnosis to development of cerebral lesions is directly correlated to initial tumor grade and stage. Several therapeutic approaches can be proposed, including best supportive care +/- corticosteroids, surgery, radiotherapy and chemotherapy. A multimodal therapy approach may achieve an improved outcome and should therefore be utilized whenever applicable.

Case presentation

We present the case of a patient with a solitary brain metastasis which appeared 11 years after a locally advanced and aggressive EOC (FIGO stage III C) and which totally regressed after surgery and adjuvant chemotherapy. Clinically, she showed progressive headaches, decreased visual acuity, balance and memory disorders associated with a confusional state. Brain CT scan and MRI documented a solitary, necrotic lesion in the left central parietal region with an important cerebral surrounding edema and initial cranial herniation. No other extracranial metastases were observed at the PET scan. Laboratory tests were in the normal range and CA 125 was moderatly increased at 81 UI/ml. The patient underwent surgical removal of tumor lesion, post-surgical whole-brain radiotherapy (WBRT) and systemic chemotherapy with carboplatin alone for six cycles. At a follow-up of 13 months, she is alive, in good clinical condition and tumor progression free.

Conclusion

The peculiarity of this case relies on the isolated brain relapse of a BRCA-1/BRCA-2 non-mutated EOC, which is uncommon and rare, and to the very long time, of 11 years, from diagnosis of primary cancer and development of brain metastasis. A multimodal, aggressive approach of this isolated brain metastasis led to a complete and prolonged tumor control.
Appendix
Available only for authorised users
Literature
1.
go back to reference Pietzner K, Oskay-Oezcelik G, El Khalfaoui K, Boehmer D, Lichtenegger W, Sehouli J: Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res. 2009, 29 (7): 2793-2798.PubMed Pietzner K, Oskay-Oezcelik G, El Khalfaoui K, Boehmer D, Lichtenegger W, Sehouli J: Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res. 2009, 29 (7): 2793-2798.PubMed
2.
go back to reference Pectasides D, Pectasides M, Economopoulos T: Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist. 2006, 11 (3): 252-260. 10.1634/theoncologist.11-3-252.CrossRefPubMed Pectasides D, Pectasides M, Economopoulos T: Brain metastases from epithelial ovarian cancer: a review of the literature. Oncologist. 2006, 11 (3): 252-260. 10.1634/theoncologist.11-3-252.CrossRefPubMed
3.
go back to reference Kolomainen DF, Larkin JMG, Badran M, A’Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME: Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol. 2002, 20 (4): 982-986. 10.1200/JCO.20.4.982.CrossRefPubMed Kolomainen DF, Larkin JMG, Badran M, A’Hern RP, King DM, Fisher C, Bridges JE, Blake PR, Barton DP, Shepherd JH, Kaye SB, Gore ME: Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol. 2002, 20 (4): 982-986. 10.1200/JCO.20.4.982.CrossRefPubMed
4.
go back to reference Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA: Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005, 25 (5): 3553-3558.PubMed Pectasides D, Aravantinos G, Fountzilas G, Kalofonos C, Efstathiou E, Karina M, Pavlidis N, Farmakis D, Economopoulos T, Dimopoulos MA: Brain metastases from epithelial ovarian cancer. The Hellenic Cooperative Oncology Group (HeCOG) experience and review of the literature. Anticancer Res. 2005, 25 (5): 3553-3558.PubMed
5.
go back to reference Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G: Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol. 2010, 21 (11): 2201-2205. 10.1093/annonc/mdq229.CrossRefPubMed Sehouli J, Pietzner K, Harter P, Münstedt K, Mahner S, Hasenburg A, Camara O, Wimberger P, Boehmer D, Buehling KJ, Richter R, El Khalfaoui K, Oskay-Ozcelik G: Prognostic role of platinum sensitivity in patients with brain metastases from ovarian cancer: results of a German multicenter study. Ann Oncol. 2010, 21 (11): 2201-2205. 10.1093/annonc/mdq229.CrossRefPubMed
6.
go back to reference Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R: Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol. 2004, 66 (3): 313-325.CrossRefPubMed Cohen ZR, Suki D, Weinberg JS, Marmor E, Lang FF, Gershenson DM, Sawaya R: Brain metastases in patients with ovarian carcinoma: prognostic factors and outcome. J Neurooncol. 2004, 66 (3): 313-325.CrossRefPubMed
7.
go back to reference Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL: Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. J Clin Oncol. 1992, 10 (10): 1553-1560.PubMed Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL: Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery. J Clin Oncol. 1992, 10 (10): 1553-1560.PubMed
8.
go back to reference Mayer RJ, Berkowitz RS, Griffiths CT: Central nervous system involvement by ovarian carcinoma: a complication of prolonged survival with metastatic disease. Cancer. 1978, 41 (2): 776-783. 10.1002/1097-0142(197802)41:2<776::AID-CNCR2820410253>3.0.CO;2-E.CrossRefPubMed Mayer RJ, Berkowitz RS, Griffiths CT: Central nervous system involvement by ovarian carcinoma: a complication of prolonged survival with metastatic disease. Cancer. 1978, 41 (2): 776-783. 10.1002/1097-0142(197802)41:2<776::AID-CNCR2820410253>3.0.CO;2-E.CrossRefPubMed
9.
go back to reference D’Andrea G, Roperto R, Dinia L, Caroli E, Salvati M, Ferrante L: Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases. Neurosurg Rev. 2005, 28 (2): 120-123. 10.1007/s10143-004-0363-4.CrossRefPubMed D’Andrea G, Roperto R, Dinia L, Caroli E, Salvati M, Ferrante L: Solitary cerebral metastases from ovarian epithelial carcinoma: 11 cases. Neurosurg Rev. 2005, 28 (2): 120-123. 10.1007/s10143-004-0363-4.CrossRefPubMed
10.
go back to reference LeRoux PD, Berger MS, Elliott JP, Tamimi HK: Cerebral metastases from ovarian carcinoma. Cancer. 1991, 67 (8): 2194-2199. 10.1002/1097-0142(19910415)67:8<2194::AID-CNCR2820670832>3.0.CO;2-#.CrossRefPubMed LeRoux PD, Berger MS, Elliott JP, Tamimi HK: Cerebral metastases from ovarian carcinoma. Cancer. 1991, 67 (8): 2194-2199. 10.1002/1097-0142(19910415)67:8<2194::AID-CNCR2820670832>3.0.CO;2-#.CrossRefPubMed
11.
go back to reference Larson DM, Copeland LJ, Moser RP, Malone JM, Gershenson DM, Wharton JT: Central nervous system metastases in epithelial ovarian carcinoma. Obstet Gynecol. 1986, 68 (6): 746-750.PubMed Larson DM, Copeland LJ, Moser RP, Malone JM, Gershenson DM, Wharton JT: Central nervous system metastases in epithelial ovarian carcinoma. Obstet Gynecol. 1986, 68 (6): 746-750.PubMed
12.
go back to reference Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L: Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003, 13 (2): 125-129. 10.1046/j.1525-1438.2003.13054.x.CrossRefPubMed Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, Selvaggi L: Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. 2003, 13 (2): 125-129. 10.1046/j.1525-1438.2003.13054.x.CrossRefPubMed
13.
go back to reference Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M: Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010, 28 (15): 2505-2511. 10.1200/JCO.2009.25.1082.CrossRefPubMed Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M: Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol. 2010, 28 (15): 2505-2511. 10.1200/JCO.2009.25.1082.CrossRefPubMed
14.
go back to reference Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K: Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res. 2013, 39 (1): 292-296. 10.1111/j.1447-0756.2012.01961.x.CrossRefPubMed Sekine M, Yoshihara K, Komata D, Haino K, Nishino K, Tanaka K: Increased incidence of brain metastases in BRCA1-related ovarian cancers. J Obstet Gynaecol Res. 2013, 39 (1): 292-296. 10.1111/j.1447-0756.2012.01961.x.CrossRefPubMed
15.
go back to reference Koul A, Loman N, Malander S, Borg A, Ridderheim M: Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report. Gynecol Oncol. 2001, 80: 399-402. 10.1006/gyno.2000.6085.CrossRefPubMed Koul A, Loman N, Malander S, Borg A, Ridderheim M: Two BRCA1-positive epithelial ovarian tumors with metastases to the central nervous system: a case report. Gynecol Oncol. 2001, 80: 399-402. 10.1006/gyno.2000.6085.CrossRefPubMed
16.
go back to reference Melichar B, Urminska H, Kohlova T, Nova M, Cesak T: Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol. 2004, 94 (2): 267-276. 10.1016/j.ygyno.2004.05.026.CrossRefPubMed Melichar B, Urminska H, Kohlova T, Nova M, Cesak T: Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature. Gynecol Oncol. 2004, 94 (2): 267-276. 10.1016/j.ygyno.2004.05.026.CrossRefPubMed
17.
go back to reference Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP: Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol Oncol. 2008, 108 (3): 505-509. 10.1016/j.ygyno.2007.11.027.CrossRefPubMed Lee YK, Park NH, Kim JW, Song YS, Kang SB, Lee HP: Gamma-knife radiosurgery as an optimal treatment modality for brain metastases from epithelial ovarian cancer. Gynecol Oncol. 2008, 108 (3): 505-509. 10.1016/j.ygyno.2007.11.027.CrossRefPubMed
Metadata
Title
A late, solitary brain metastasis of epithelial ovarian carcinoma
Authors
Raffaele Longo
Christian Platini
Nada Eid
Clémence Elias-Matta
Thaar Buda
Denis 'Nguyen
Philippe Quétin
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-543

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine